For healthcare professionals only


In brief

BMJ 2004; 329 doi: (Published 28 October 2004) Cite this as: BMJ 2004;329:994

European agency to review safety of COX 2 inhibitors: The European Medicines Evaluation Agency has announced that it will review “all aspects of cardiovascular safety” of all COX 2 (cyclo-oxygenase-2) inhibitors in the light of newly available data and the withdrawal of rofecoxib (Vioxx) (BMJ 2004;329: 816, 9 Oct).

Byrne takes up post in WHO: David Byrne, the European …

View Full Text

Log in

Log in through your institution


* For online subscription